Group 1 - The core announcement is about the approval of the ethical review for the Phase II clinical trial of "Nano Carbon Iron Suspension Injection" by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., a subsidiary of Chongqing Laimei Pharmaceutical Co., Ltd., which is controlled by Guangxi Wuzhou Zhongheng Group Co., Ltd. [1] - The Phase I clinical trial of Nano Carbon Iron has been successfully completed, focusing on safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors [1][2] - The Phase II clinical trial aims to validate the effectiveness and safety of the drug in combination with radiotherapy, providing critical data for the final product application [1][3] Group 2 - Nano Carbon Iron is a next-generation nano drug developed based on the company's existing product, utilizing Fe2+ as an effective anti-cancer component and nano carbon as a carrier, targeting the iron death pathway to exert anti-cancer effects [3] - The drug is administered intratumorally and is expected to enhance the efficacy of radiotherapy, particularly in large, hypoxic tumors that are difficult to control with radiotherapy alone [3] - As of the announcement date, the cumulative R&D expenses for Nano Carbon Iron amount to approximately 98.06 million RMB (data unaudited) [4]

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection" [1][2] Group 1: Product Development - The drug "Nano Carbon Iron" is a next-generation nano drug developed based on Laimei's existing product, utilizing Fe2+ as the active anti-cancer ingredient and nano carbon as its carrier [1] - The mechanism of action involves regulating ferroptosis pathways to exert anti-cancer effects, with the drug administered via intratumoral injection to inhibit tumor growth [1] Group 2: Clinical Trial and Mechanism - The approved clinical trial will explore the safety and potential efficacy of the combination of "Nano Carbon Iron" and standard radiotherapy in treating solid tumors [2] - Research indicates that the mechanisms of action of "Nano Carbon Iron" and radiotherapy are complementary, potentially enhancing the local treatment effects, especially in large, hypoxic tumors that are difficult to control with radiotherapy alone [2]